185 related articles for article (PubMed ID: 34378245)
1. A randomized, open-label, two-period crossover bridging study on fuzuloparib capsules of different specifications in healthy Chinese volunteers.
Jiang X; Tao Y; Liu Y; Shi P; Li T; Sun F; Cao Y; Wang C
Br J Clin Pharmacol; 2022 Mar; 88(3):1087-1093. PubMed ID: 34378245
[TBL] [Abstract][Full Text] [Related]
2. Bioequivalence Study of Palbociclib Capsules in Healthy Chinese Subjects Under Fasting and Fed Conditions.
Chu NN; Zhang L; Wang J; Gu X; Ding Y; Huang K; Que LL; He Q
Clin Drug Investig; 2022 Jan; 42(1):53-63. PubMed ID: 34837169
[TBL] [Abstract][Full Text] [Related]
3. A single-dose, randomized crossover study in healthy Chinese subjects to evaluate pharmacokinetics and bioequivalence of two capsules of calcium dobesilate 0.5 g under fasting and fed conditions.
Liu Y; Cheng J; Liang L; Qian W; Ou M; Zhang M; Wang Y; Wang Y; Peng K; Jia J
PLoS One; 2023; 18(4):e0284576. PubMed ID: 37083730
[TBL] [Abstract][Full Text] [Related]
4. Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers.
Chen X; Yang F; Zhao J; Tang Q; Heng J; Deng J; Zhang J; Chen Y; Li K; Wang J
Cancer Chemother Pharmacol; 2022 Jan; 89(1):141-148. PubMed ID: 34851444
[TBL] [Abstract][Full Text] [Related]
5. Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects.
Hu L; Dou T; Sun Q; Tang L; Cai M; Qian W; Wang H
Invest New Drugs; 2023 Apr; 41(2):276-283. PubMed ID: 36800130
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients with Colorectal or Breast Cancer Under Fed Conditions: A Multicenter, Randomized, Open-Label, Three-Period, and Reference-Replicated Crossover Study.
Wang CJ; Li T; Lin PP; Tao Y; Jiang X; Li X; Wen Q; Cao Y
Adv Ther; 2021 Sep; 38(9):4798-4814. PubMed ID: 34347254
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Bioequivalence of Two Formulations of Valsartan 80 mg Capsules: A Randomized, Single Dose, 4-Period Crossover Study in Healthy Chinese Volunteers Under Fasting and Fed Conditions.
Wu Q; Wang X; Chen Q; Zou Y; Xu X; Li T; Yu C; Zhu F; Zhang KE; Jia J; Liu Y
Drug Des Devel Ther; 2020; 14():4221-4230. PubMed ID: 33116410
[TBL] [Abstract][Full Text] [Related]
8. Bioequivalence study of two formulations of flupirtine maleate capsules in healthy male Chinese volunteers under fasting and fed conditions.
Liu Y; Huo H; Zhao Z; Hu W; Sun Y; Tang Y
Drug Des Devel Ther; 2017; 11():3441-3448. PubMed ID: 29238169
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalence study of two perindopril tert-butylamine tablet formulations in healthy Chinese subjects under fasting and fed conditions: A randomized, open-label, single-dose, crossover trial.
Li Q; Hao Z; Yu Y; Tang Y
Biomed Pharmacother; 2021 Mar; 135():111221. PubMed ID: 33433351
[TBL] [Abstract][Full Text] [Related]
10. Bioequivalence of cefalexin in healthy Chinese subjects.
Lv X; Zhong G; Yao H; Wu J; Ye S
Int J Clin Pharmacol Ther; 2021 Nov; 59(11):725-733. PubMed ID: 34448694
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence of levamlodipine besylate tablets in healthy Chinese subjects: a single-dose and two-period crossover randomized study.
Li X; Wang C; Li T; Liu Y; Liu S; Tao Y; Ma Y; Gao X; Cao Y
BMC Pharmacol Toxicol; 2020 Nov; 21(1):80. PubMed ID: 33213527
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, Bioequivalence, and Safety Evaluation of Two Oral Formulations of Calcium Dobesilate Capsules in Healthy Chinese Volunteers Under Fasting and Fed Conditions.
Wang Y; Liu Y; Tang L; Gao J; Li H; Dai X; Chen R; Wang F
Clin Pharmacol Drug Dev; 2024 Apr; 13(4):360-366. PubMed ID: 38226890
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers.
Liu MY; Wang S; Yao WF; Wu HZ; Meng SN; Wei MJ
Clin Ther; 2009 Apr; 31(4):784-92. PubMed ID: 19446151
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and bioequivalence studies of fluvoxamine maleate tablets in healthy Chinese subjects.
She DP; He Y; Li MQ; Su L; Ren D; Huang XH; Zhang YH; Hu HT; Deng DC; Wu JL
Biomed Chromatogr; 2023 Jun; 37(6):e5613. PubMed ID: 36849133
[TBL] [Abstract][Full Text] [Related]
15. Bioequivalence and Safety Assessment of Two Formulations of Metformin Hydrochloride Sustained-Release Tablets (Yuantang
Sun ML; Liu HJ; Luo XD; Wang Y; Zhang W; Liu C; Wang X
Drugs R D; 2022 Mar; 22(1):51-60. PubMed ID: 35061235
[TBL] [Abstract][Full Text] [Related]
16. The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study.
Li KY; Liang JP; Hu BQ; Qiu Y; Luo CH; Jiang Y; Lin XP; Yang N
Clin Ther; 2010 Aug; 32(9):1674-80. PubMed ID: 20974325
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Bioequivalence of Cefprozil for Suspension and Granule Formulation in Healthy Chinese Volunteers: Two Single-Dose Crossover Studies.
Lin PP; Wang CJ; Liu YP; Li T; Gao XM; Ma YP; Shi P; Li X; Wang LX; Cao Y
Adv Ther; 2021 Feb; 38(2):1130-1142. PubMed ID: 33340343
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and Bioequivalence Study of Eldecalcitol Soft Capsules in Healthy Chinese Subjects.
Li T; Sun F; Liu Y; Su L; Shi P; Li X; Liu S; Wang C; Shen L; Cao Y; Wang S
Clin Pharmacol Drug Dev; 2022 Dec; 11(12):1474-1480. PubMed ID: 36018219
[TBL] [Abstract][Full Text] [Related]
19. A randomized single-dose, two-period crossover bioequivalence study of two fixed-dose Paracetamol/Orphenadrine combination preparations in healthy volunteers under fasted condition.
Cheah KY; Mah KY; Pang LH; Ng SM; Wong JW; Tan SS; Tan HZ; Yuen KH
BMC Pharmacol Toxicol; 2020 Jun; 21(1):45. PubMed ID: 32576287
[TBL] [Abstract][Full Text] [Related]
20. Effect of food on the pharmacokinetics and safety profiles of a new PARP inhibitor fuzuloparib capsules in healthy volunteers.
Du P; Long Y; Wang M; Huang Y; Wang Y; Chen X; Lin Y; Wu J; Shen J; Jia Y
Cancer Chemother Pharmacol; 2024 May; ():. PubMed ID: 38703321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
